000 02354na a2200325 4500
999 _c297
_d297
003 PC297
005 20210625062753.0
008 130622s2013 xxx||||| |||| 00| 0 eng d
040 _cH12O
041 _aeng
100 _aLópez Muñoz, Francisco
_92616
_eInstituto de Investigación i+12
100 _aRubio Valladolid, Gabriel
_9726
_ePsiquiatría
245 0 0 _aMapping the scientific research on atypical antipsychotic drugs in Spain: a bibliometric assessment.
_h[artículo]
260 _bActas españolas de psiquiatría,
_c2013
300 _a41(6):349-60.
500 _aFormato Vancouver: López-Muñoz F, Rubio G, Molina JD, Shen WW, Pérez-Nieto MA, Moreno R, et al. Mapping the scientific research on atypical antipsychotic drugs in Spain: a bibliometric assessment. Actas Esp Psiquiatr. 2013 Nov-Dec;41(6):349-60.
501 _aPMID: 24203507
504 _aContiene 41 referencias
520 _aWe carried out a bibliometric study on the scientific publications in relation to atypical antipsychotic drugs (AADs) in Spain. Methods: We used the EMBASE and MEDLINE databases and we applied some bibliometric indicators of paper production and dispersion (Price’s law and Bradford’s law, respectively). We also calculated the participation index of the different countries and correlated the bibliometric data with some social and health data (total per capita expenditure on health and gross domestic expenditure on research and development). Results: We collected 656 original papers published between 1988 and 2011. Our study results fulfilled Price’s law with scientific production on AADs showing exponential growth (correlation coefficient r = 0.9693, vs. r = 0.9177 after linear adjustment). The most widely studied drugs were risperidone (181 papers), olanzapine (143), clozapine (94), and quetiapine (74). Division into Bradford zones yielded a nucleus occupied by the European Psychiatry and European Neuropsychopharmacology (70 articles). Totally 194 different journals were published, with 5 of the first 10 used journals having an impact factor being greater than 4. Conclusion: The publications on AADs in Spain have undergone exponential growth over the studied period, without evidence of reaching a saturation point.
710 _9625
_aInstituto de Investigación imas12
710 _9150
_aServicio de Psiquiatría
856 _uhttps://pubmed.ncbi.nlm.nih.gov/24203507/
_yAcceso libre
942 _n0
_2ddc
_cART